| A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. | |
| | |
MedLine Citation:
|
PMID: 3192388 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2-21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued. |
| | |
Authors:
|
B L Zidar; S Green; H I Pierce; R W Roach; S P Balcerzak; L Militello |
Related Documents
:
|
21803018 - Outcomes of hodgkin's lymphoma patients with relapse or progression following autologou... 15559058 - Pleurectomy and decortication for malignant mesothelioma. 17947608 - Parenteral nutrition prolongs the survival of patients associated with malignant gastro... 19632388 - Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. 9308948 - Radiotherapy for pituitary adenoma: long-term outcome and sequelae. 21803018 - Outcomes of hodgkin's lymphoma patients with relapse or progression following autologou... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Investigational new drugs Volume: 6 ISSN: 0167-6997 ISO Abbreviation: Invest New Drugs Publication Date: 1988 Sep |
Date Detail:
|
Created Date: 1989-01-12 Completed Date: 1989-01-12 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 8309330 Medline TA: Invest New Drugs Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 223-6 Citation Subset: IM |
Affiliation:
|
Allegheny General Hospital, Seattle. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Cisplatin / adverse effects, therapeutic use* Drug Evaluation Female Humans Male Mesothelioma / drug therapy*, mortality Middle Aged Southwestern United States |
| Grant Support | |
ID/Acronym/Agency:
|
CA-35117/CA/NCI NIH HHS; CA-35281/CA/NCI NIH HHS; CA-37429/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
15663-27-1/Cisplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast ca...
Next Document: Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refrac...